We create innovative treatments for nervous system damage due to injury or disease.
NervGen Pharma
NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial. The company’s lead target indication is spinal cord injury.
Phase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury
NervGen is actively recruiting for a landmark Phase 1b/2a proof-of-concept clinical trial of
NVG-291 in individuals with spinal cord injury.
For information regarding recruitment, the call center phone number is +1 (855) 559-6902.
View our Corporate Presentation
Stay Connected
Subscribe to our mailing list to stay up to date
The Latest
News Release
May 16, 2024
NervGen reported its financial and operational results for the first quarter ended March 31, 2024.
News Release
May 7, 2024
NervGen announced that its June 4, 2024 AGM Management Information Circular is being delivered to its shareholders; Chairman & Co-Founder is not standing for re-election and will transition to an advisor to the Board.
Article
July 28, 2022
Unlike existing treatments that focus on rehabilitation or reducing the risk of an additional stroke, the experimental drug targets the "stickiness" that can prevent injured brain tissue from functioning as it should